Cumberland Pharmaceuticals (NASDAQ:CPIX) will announce its earnings results after the market closes on Wednesday, August 14th. Analysts expect the company to announce earnings of $0.05 per share for the quarter.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.22. The business had revenue of $11.90 million for the quarter, compared to analysts’ expectations of $10.70 million. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. On average, analysts expect Cumberland Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ:CPIX traded down $0.14 during trading hours on Friday, hitting $5.66. The company had a trading volume of 5,790 shares, compared to its average volume of 31,586. The firm has a market cap of $94.00 million, a P/E ratio of -47.17 and a beta of 0.15. The company’s 50-day simple moving average is $6.03. Cumberland Pharmaceuticals has a 52 week low of $4.83 and a 52 week high of $7.00. The company has a quick ratio of 1.67, a current ratio of 2.07 and a debt-to-equity ratio of 0.36.
In other news, Director Gordon R. Bernard sold 7,471 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $5.77, for a total transaction of $43,107.67. Following the sale, the director now owns 59,673 shares in the company, valued at approximately $344,313.21. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gordon R. Bernard sold 8,876 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $6.22, for a total transaction of $55,208.72. Following the sale, the director now owns 95,388 shares in the company, valued at approximately $593,313.36. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 11,150 shares of company stock worth $70,165 and have sold 51,423 shares worth $315,809. Insiders own 39.38% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.25 price target on the stock in a report on Thursday, May 23rd.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.